C-REACTIVE PROTEIN AND ADIPOSITY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
Article Sidebar
Main Article Content
Abstract
C- reactive protein (CRP) is one of the biomarkers that elevated in obese women with polycystic ovary syndrome (PCOS). PCOS is the most common endocrine disorder, affecting 5-10% of women at reproductive age. It is also called hyperandrogenic anovulation (HA) due to a hormones imbalance in women. Risk factors that predisposing to PCOS including; obesity, decreased physical exercise and family history with PCOS. This syndrome is characterized by overproduction of androgen and ovulatory dysfunction which are accompanied by many clinical and biochemical features including hirsutism, acne, ovary cysts, menstrual irregularities, obesity, dyslipidemia, hyperinsulinemia and glucose intolerance. This study was aimed to: 1. measure serum levels of CRP, total cholesterol, triglyceride, LDL, HDL, VHDL, in addition to calculate Body Mass Index (BMI), in women with PCOS and to compare the results with that of healthy women (Controls). 2. Compare serum CRP, total cholesterol, triglyceride, LDL, HDL and VHDL in normal weight women patients with BMI matched controls. 3. Compare serum CRP, total cholesterol, triglyceride, LDL, HDL and VHDL in obese women patients with BMI matched controls. The present study includes thirty (30) women with PCOS and thirty (30) healthy women served as control. All subjects' age range was between 15 to 40 years, then each group classified into two subgroups depending on BMI. Blood samples were collected and serum was obtained to measure CRP and lipid profile. Polycystic ovarian women group exhibited significantly increased serum levels of CRP (p= 0.001), cholesterol (p= 0.009), triglyceride (p=0.0001) and LDL (p= 0.0001) when compared to healthy control group. BMI also increased in polycystic ovarian women group although it is statistically not significant when compared to controls. Moreover, the serum levels of LDL and HDL in polycystic ovarian women showed non statistical differences when compared to the controls. Our results indicated that CRP is one of biomarkers in obese women with PCOS. Its high level associated with adiposity rather than PCOS itself. PCOS has negative impact on lipid metabolism in normal body weight women and adiposity is played important role in pathogenesis of lipid abnormality in obese women with polycystic ovary syndrome. We concluded from this study that obese women with PCOS having high CRP therefore are more prone to dyslipidemia (atherogenic) and they should routinely screen to prevent further metabolic and cardiac diseases.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1-Pepys M, Hirschfield G. CPR: critical update. J Clin Invest.2003;112:1805-12.
2. Ridker P, Cook N. Clinical usefulness of very high & very low levels of CPR across the full range of Framingham Risk Scores. Cir.2004;109:1955-9.
3-Dumesic D, Oberfield S, Stener E, Marshall J. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology & molecular genetics of PCOS.EndocrRev.2015;36:487-525.
4-Azziz R, Carmina E, Dewailly D. Androgen Excess & PCOS Society criteria for PCOS. Fertil Steril.2009;91:456-88.
5-De Leo V, Musacchio M, Cappelli V, Massaro MG. Genetic, hormonal &metabolic aspects of PCOS. Reproductive Biol and Endo.2016;14(1):38.
6-Moran L, Misso M, Marsh K, Noakes M. Dietary composition in the treatment of PCOS. Hum Reprod.2013;19(5):432-3.
7-Legro R, Arslanian S, Ehrmann D, Hoeger K. Diagnosis and treatment of PCOS.J of Clin Endo &Metab.2013;98:4565-6.
8-Susan B, Ying C.Disorders of Menstrual Cycle, Nineteenth Edition. Ash Monga and Stephen Dopps public.2011;43-45.
9-Tigue K. Screening and interventions for overweight and obesity in adults. Ann Intern Med 2003;139(11):933-949.
10-Iuhas C, Costin N, Mihu D. High sensitivity CPR in patients with PCOS, Rom J Diab Nutr Metab Dis.2012;19(4):389-96.
11-Ramanand S , Jaiprakash B, Raparti GT, Ravi R. Ghanghas. High sensitivity CPR & clinical characteristics, endocrine, metabolic profile in indian women with PCOS. Int J Reprod Contracept Obstet Gynecol.2014;3(1):118-26
12-Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, Muggeo M, Moghetti P. Body fat & insulin resistance independently predict increased serum CPR in hyperandrogenic women with PCOS. Eur J Endocrinol.2009;161:737-45.
13-Koppalli S, Reddy BV, Vijayaraghavan R, Paluru R, Rangarao T & Sarma SS. Evaluation of serum CRP conc.in reproductive women with PCOS. 2016; 28: 744-56.
14- Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F. Circulating inflammatory markers in PCOS. Fertil Steril.2011;95:1048-58.
15- Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. CRP in healthy subjects:associations with obesity, insulin resistance & endothelial dysfunction:a potential role for cytokines originating from adipose tissue Arterioscler Thromb Vasc Biol.1999;19:972-8.
16-Karoli R, Fatima J, Siddiqi Z, Vatsal P, Sultania AR. Study of early atherosclerotic markers in women with PCOS. Indian J Endocrinol Metab. 2012; 16: 1004 - 8.
17-Manjunatha S, Amruta S, Shaktiprasad H, Veena H. Effect of PCOS on Lipid Profile, Scholars J of App Med Sci.2014;2(3):1153-5.
18-Barter P, Brewer J, Chapman M, Henneckens C, Rader D, Tall A. Cholesteryl ester transfer protein,a novel target for raising HDL& inhibiting atheroscelerosis. Arterioscler Thromb Vasc Biol. 2003; 23:160-7.
19-Lambrinoudaki I, Christodoulakos G, Rizos D, Economou E, Argeitis J, Vlachou S. Endogenous sex hormones and risk factors for atherosclerosis in health Greek postmenopausal women. Eur J Endocrinol. 2006;154(6):907-16.
20-Teede H.J, Hucthison S.K, Zoungas S. Management of insulin resistance in PCOS.Trends Endocrinol Metab.2007;18:273-9.
21-Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. PCOS is Associated with Atherogenic Changes in Lipoprotein Particle. Clin Endocrinol.2011;75:76-82.
22-Echiburú B, Pérez-Bravo F, Maliqueo M, Ladrón de Guevara A, Gálvez C, Crisosto N, et al. CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with PCOS. Gynecol Endocrinol.2012;28:516-20.
23-Gateva A, Kamenov Z. Cardiovascular Risk Factors in Bulgarian Patients with PCOS &/ or Obesity. Obstet Gynecol Int.2012;10:1155-61.
24-Cristian-Ioan I, Nicolae C, Dan M. Lipid Parameters in Patients with PCOS. Original Research. 2012;31:27-32.